{"doi":"10.1001/jamanetworkopen.2021.14606","title":"Inclusion of Underrepresented Groups in Preclinical Alzheimer Disease Trials—Opportunities Abound","abstract":"In the search for treatments to delay or halt the progression of Alzheimer disease (AD), researchers see promise in clinical trials that enroll people without cognitive decline who exhibit neuropathology traditionally associated with AD, namely amyloid plaques and tau tangles. The Anti-amyloid Treatment in Asymptomatic Alzheimer trial (A4 study) of an anti- amyloid (A) monoclonal antibody in older adults with preclinical neuropathological features of AD is the foremost example of this effort. 1 Lead investigators of A4 study set the laudable goal of requiring that at least 20% of people screened for enrollment at each recruitment site would be from minoritized racial and ethnic groups. This objective is a welcome deviation in the AD field, which has underincluded these populations in preclinical and biomarker-based studies, despite the disproportionate burden of AD in minoritized populations. 2 Despite these efforts, the A4 trial fell short of its recruitment goal: 86% of those screened and 88% who remained eligible after initial screening and an amyloid positron emission tomography (PET) scan were non-Hispanic White individuals. As preclinical AD studies continue to expand, trials such as the A4 study present important opportunities to investigate recruitment-and enrollment-based factors relevant to inclusion of minoritized racial and ethnic groups.","journal":"JAMA Network Open","year":2021,"id":163946,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":40,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9478,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":497382,"name":"Andrea Gilmore‐Bykovskyi","orcid":"0000-0003-4930-3558","position":1,"is_corresponding":false},{"id":685545,"name":"Kacie Deters","orcid":null,"position":2,"is_corresponding":false},{"id":49960,"name":"Jennifer J. Manly","orcid":"0000-0002-9481-7497","position":0,"is_corresponding":true}],"reference_count":5,"raw_metadata":null,"created_at":"2026-07-18T23:45:27.031465Z","pmid":"34228130","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}